Business Context and Reporting Period
Company: Altria Group, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Altria is a leading U.S. tobacco company with a portfolio including combustible cigarettes (Marlboro), cigars (Black & Mild), moist smokeless tobacco (Copenhagen, Skoal), oral nicotine pouches (on!), and e-vapor products (NJOY). The company also holds significant equity investments in Anheuser-Busch InBev (ABI) and Cronos Group Inc.
Key Financial Metrics
| Metric (in millions, except per share) | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 |
|---|---|---|
| Net Revenues | $6,259 | $18,044 |
| Gross Profit | $3,808 | $10,763 |
| Operating Income | $3,152 | $8,359 |
| Net Earnings | $2,293 | $8,225 |
| Diluted EPS | $1.34 | $4.75 |
| Operating Cash Flow (9M) | $5,413 | |
| Total Debt (Carrying Value) | $25,155 | |
| Cash and Cash Equivalents | $1,897 |
Material Changes vs. Prior Comparable Period
- Net Earnings: Increased 35.5% year-over-year for the nine months ended September 30, 2024, driven primarily by a $2.7 billion pre-tax gain from the sale of IQOS System commercialization rights and favorable results from equity investments.
- Revenues: Decreased 2.5% for the nine-month period due to lower shipment volumes in the smokeable products segment, partially offset by higher pricing and growth in oral tobacco products.
- Asset Impairment: Recorded a non-cash, pre-tax impairment charge of $354 million related to the Skoal trademark in the oral tobacco segment due to declining sales volumes and competitive pressures from oral nicotine pouches.
- Investment Activity: Completed the sale of a portion of its ABI investment (ABI Transaction) in March 2024, generating approximately $2.4 billion in pre-tax cash proceeds, which were used to fund accelerated share repurchases.
Guidance, Outlook, and Management Commentary
- Optimize & Accelerate Initiative: Approved in October 2024, this multi-phase initiative aims to modernize operations and deliver at least $600 million in cumulative cost savings over five years. Initial pre-tax charges of $100 million to $125 million are expected, with the majority recorded by the end of the first half of 2025.
- Dividends: The Board approved a 4.1% increase in the quarterly dividend to $1.02 per share, resulting in an annualized rate of $4.08. The company targets mid-single-digit dividend growth annually through 2028.
- Share Repurchases: Under the January 2024 program (increased to $3.4 billion), the company repurchased $3.09 billion of stock in the first nine months of 2024. Approximately $310 million remains available under the program.
- Market Trends: Management notes continued pressure on adult tobacco consumer discretionary income due to inflation, leading to a shift toward discount cigarette brands. The e-vapor category grew approximately 30% year-over-year, driven largely by illicit disposable products, which has negatively impacted pod-based volumes.
- Regulatory Environment: The FDA has delayed a decision on the menthol ban indefinitely. NJOY received Marketing Granted Orders (MGOs) for four menthol e-vapor products in June 2024, triggering $250 million in contingent acquisition payments.
Investor Verification Checklist
- IQOS Gain Sustainability: Verify the one-time nature of the $2.7 billion gain from the IQOS sale and its impact on reported earnings versus adjusted earnings.
- Skoal Impairment Risk: Assess the sensitivity of the Skoal trademark valuation to further declines in moist smokeless tobacco (MST) volumes and the potential for additional impairment charges.
- Illicit E-Vapor Impact: Monitor the growth of illicit disposable e-vapor products and their effect on NJOY's volume growth and market share.
- Debt-to-EBITDA Ratio: Confirm the company's ability to maintain its target debt-to-Consolidated EBITDA ratio of approximately 2.0x given current leverage levels (2.1x as of Sept 30, 2024).
- Regulatory Outcomes: Track the status of FDA decisions on menthol bans, characterizing flavors in cigars, and the resolution of patent infringement litigation involving NJOY and JUUL.